

FORM 51-102F3
Material Change Report

ITEM 1 Name and Address of Company

Braxia Scientific Corp ("Braxia" or the "Company")
1430 Hurontario Street
Mississauga, Ontario
L5G 3H4

ITEM 2 Date of Material Changes

- (a) Name Change: April 29, 2021
- (b) Class Action Proceeding: May 3, 2021
- (c) Introduction of Braxia Health: May 5, 2021

ITEM 3 News Releases

- (a) Name Change: A news release announcing the material change related to the change of the Company's name was issued through the facilities of Canada Newswire/Cision on May 3, 2021 and subsequently filed on SEDAR.
- (b) Class Action Proceeding: A news release announcing the material change related to the class proceeding filed against the Company in British Columbia was issued through the facilities of Canada Newswire/Cision on May 3, 2021 and subsequently filed on SEDAR.
- (c) Braxia Health: A news release announcing the material change related to the rebranding of the Company's clinics "Braxia Health" was issued through the facilities of Canada Newswire/Cision on May 5, 2021 and subsequently filed on SEDAR.

ITEM 4 Summary of Material Changes

- (a) Name Change: The Company changed its name from "Champignon Brands Inc." to "Braxia Scientific Corp." on April 29, 2021.
- (b) Class Action Proceeding: On May 3, 2021 the Company was served with a notice of civil claim in a proposed class proceeding in British Columbia against the Company, its CEO, certain of its former officers, a shareholder, and underwriters which were engaged in connection with a private placement financing for the Company in June 2020.
- (c) Braxia Health: On May 5, 2021 the Company announced the rebranding of the Company's clinics "Braxia Health".

ITEM 5 Full Description of Material Changes

(a) Name Change

The Company changed its name from "Champignon Brands Inc." to "Braxia Scientific Corp." on April 29, 2021. The name change reflects the Company's commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company's ketamine and psychedelic derivative research and drug development priorities. Braxia Scientific's overarching aim is to shape the future of treatment for people suffering from depression and other mental health disorders.

(b) Class Action Proceeding

On May 3, 2021 the Company was served with a notice of civil claim in a proposed class proceeding in British Columbia against the Company, its CEO, certain of its former officers, a shareholder, and underwriters which were engaged in connection with a private placement financing for the Company in June 2020. The claim is based on allegations relating to the Company's disclosure documents regarding the value of four acquisitions made by the Company in 2020 and related matters. The plaintiff is seeking an unspecified amount of damages for the proposed class. The Company stated that it intends to vigorously defend the claim.

(c) Braxia Health: On May 5, 2021 the Company announced the rebranding of the Company's network of research and treatment clinics to "Braxia Health". The Company also provided an update on its plan to expand its research and treatment and clinic footprint to address significant opportunities in the North American multi-billion-dollar mental healthcare market.

ITEM 6 Reliance on Subsection 7.1(2) of National Instrument 51-102

Not applicable. This report is not being filed on a confidential basis.

ITEM 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

ITEM 8 Executive Officer

For further information, please contact Peter Rizakos, General Counsel of the Company, at (647) 204-3083.

ITEM 9 Date of Report

May 6, 2021.